GLP-1 receptor agonists like semaglutide work by delivering medication into subcutaneous tissuethe layer of fat beneath your skin
Before administering any shots, Dr
It does not require refrigeration, making it more convenient for travel and storage than many injectables
Full disclaimer 1.Retatrutide (LY3437943) is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly 2.Phase 2 trials demonstrated up to 24.2% body weight loss at 48 weeksthe highest weight loss ever reported in a Phase 2 obesity trial 3.Triple mechanism activates multiple metabolic pathways: appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy expenditure (glucagon) 4.Currently in Phase 3 TRIUMPH trials for weight management, type 2 diabetes, NASH, and osteoarthritis
These considerations inform the development of Setria Glutathione